CALLALY
20.11.2020 12:38:09 CET | Business Wire | Press release
The Tampliner, the period-care innovation created by UK-based B-corp Callaly , has been recognised in TIME’s 100 Best Inventions of 2020 - its annual list of the 100 Best Inventions that are making the world better, smarter and even a bit more fun. Callaly is one of only eight British companies to make this year’s list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005371/en/
Callaly set out to improve the $34bn period care industry with the launch of the Tampliner, a completely new period care product and first design upgrade to the tampon in 90 years. It is a 2-in-1 period product that combines an organic cotton tampon with a soft mini-liner for extra protection against leaks, connected by a ‘virtual applicator’.
The Tampliner, which is designed and manufactured in the UK and was launched in February 2020, was invented by Dr Alex Hooi, a senior British gynaecologist and Fellow of the Royal College of Obstetricians and Gynaecologists and developed by garment technologist Ewa Radziwon, who trained at London College of Fashion.
The British manufactured product is protected by four granted patent families covering 80% of the global market. It is now being exported across Europe in Sweden, the Netherlands and Ireland, and has been trialled with positive results in China.
Callaly, which has raised £13.2m through private investment and government funding, is backed by Innovate UK, having received five tranches totalling £3.9m to support the development and manufacture of the Tampliner. The company employs 20 people in its London HQ.
Callaly’s founder and CEO, Thang Vo-Ta said: “Our whole team is honoured that the Tampliner has been recognised by TIME as a pioneering invention. The period-care industry has been failing people for decades. Little to no R&D in the space means that many people with periods are compromising their health, comfort and convenience, with no choice but to put up with the dissatisfaction they feel. With our 2-in-1 invention we set out to address these problems from every angle and truly make people’s lives better. The Tampliner paves the way for further product innovations to radically improve people’s experiences of periods across the globe.”
Dr Ian Campbell, Executive Chair (Interim) Innovate UK said: "Innovate UK has been proud to support Callaly’s journey over the years, from innovation to manufacturing and now global expansion. This recognition from TIME acknowledges the great potential of R&D-backed British businesses like Callaly to change the world for the better."
Image of the tampliner can be found here .
See the full list here: www.time.com/best-inventions-2020
See the international cover of TIME featuring the 100 Best Inventions of 2020 here: bit.ly/3lJM8ss
ENDS
About Callaly:
British based Callaly is a certified B Corp- a for-profit company that’s committed to using business as a force for good. There are over 3,500 certified B Corps in the world including Danone N. America and Unilever’s Ben & Jerry. Every decision Callaly makes, no matter how small, is taken with an eye on the wider global impact. Callaly donates at least 1% of sales to charities supporting women & children.
Callaly offers a range of high quality period care products managed through its ISO9001 based Quality Management System including award-winning Tampliners, pantyliners, day pads, night pads and tampons- all in a range of different absorbencies. All the products are made with 100% organic cotton and are free from dioxins, perfumes, and pesticides. The Earth-friendly products are all wrapped in sustainable packaging.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom